skip to main content

Overactive bladder symptoms associated with genitourinary syndrome of menopause in a woman receiving an aromat

Instant feedback + full explanation. One question, done properly.

HardLUTSOveractive bladder symptoms associated with genitourinary syndrome of menopause in a woman receiving an aromatase inhibitorMSRA

A 63-year-old woman reports 5 months of urinary urgency, daytime frequency and nocturia. She has no stress leakage, dysuria, visible haematuria, recurrent UTI, voiding difficulty or sensation of incomplete emptying. Urine culture is negative and post-void residual volume is 28 mL. A 6-week supervised bladder-training programme has not provided sufficient benefit. She is postmenopausal and also reports vaginal dryness and dyspareunia. Examination shows pale, thin vaginal epithelium consistent with genitourinary symptoms associated with menopause. She has used vaginal moisturisers and lubricants regularly without worthwhile relief. Three years ago she was treated for oestrogen receptor-positive breast cancer and remains on adjuvant anastrozole. Her breast cancer follow-up is otherwise stable. What is the most appropriate next management step to address the likely menopausal contributor to her urinary symptoms?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Discuss vaginal oestrogen and work with her breast cancer specialist to agree treatment options

Explanation lettering: E = shown as A · A = shown as B · D = shown as C · B = shown as D · C = shown as E

She has overactive-bladder-type LUTS with low residual urine and no evidence of infection or voiding dysfunction. The accompanying vaginal dryness, dyspareunia and atrophic examination findings indicate genitourinary symptoms associated with menopause, for which NICE advises vaginal oestrogen in women who also have overactive bladder symptoms. However, she is currently taking an aromatase inhibitor for previous ER-positive breast cancer. After non-hormonal measures have failed, NICE advises working with a breast cancer specialist to identify appropriate treatment options before vaginal oestrogen is considered, because vaginal oestrogen may lessen aromatase-inhibitor efficacy and the recurrence-risk evidence is uncertain. B would be appropriate for a woman without this aromatase-inhibitor exception, but bypasses the required specialist discussion. C and D can be appropriate pharmacological treatments for persistent overactive bladder, but neither addresses her clinically evident genitourinary menopause symptoms; they do not remove the need to manage the atrophic component safely. E is inappropriate: systemic HRT is not a treatment for urinary incontinence or overactive bladder and is unsuitable in this context of ER-positive breast cancer treated with anastrozole.

Reference: NICE NG123: Urinary incontinence and pelvic organ prolapse in women: management (2019) — https://www.nice.org.uk/guidance/ng123/chapter/recommendations NICE NG23: Menopause: identification and management (Updated 15 April 2026) — https://www.nice.org.uk/guidance/ng23/chapter/Recommendations